Fig. 2From: Octamer-binding transcription factor 4-positive circulating tumor cell predicts worse treatment response and survival in advanced cholangiocarcinoma patients who receive immune checkpoint inhibitors treatmentPFS in the none CTC, OCT4−CTC, and OCT4+CTC groups. Comparison of PFS among none CTC, OCT4−CTC, and OCT4+CTC groups (A); comparison of PFS between none CTC & OCT4−CTC and OCT4+CTC groups (B)Back to article page